JAMESTOWN — Jamestown Regional Medical Center (JRMC) has received recognition from Becker’s Hospital Review as one of 455 ...

Decision-making forms the core of hospital patient care, involving an array of clinicians whose duties span diagnosis, ...

A new comparative study led by researchers at the UNC School of Medicine found that a new therapy for prevention of recurrent ...

RBX2660 has been granted Orphan Drug status, Fast Track status and gained Breakthrough Therapy Designation from the FDA in October 2015 for its potential to prevent recurrent C. diff. infection.

Patients suffering from a recurrent C diff infection have benefited from Rebiotix's microbiome treatment. Skip to main content Wednesday 30 April 2025 . twitter linkedin facebook rss. User account ...

Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...

Jamestown Regional Medical Center (JRMC) has received recognition from Becker’s Hospital Review as one of 455 hospitals in ...

A nephrology unit at Detroit-based Henry Ford Hospital has lowered Clostridioides difficile infections by 90% since 2023. Leaders at the hospital credit the progress to the Comprehensive Unit-based ...

Sixty-four more hospitals had a rate of zero, the lowest rate possible, for C. diff infections compared to CMS’ 2023 list. Here are the 455 hospitals by state: Alabama. Mizell Memorial Hospital ...

Treatment with live-jslm (Rebyota) was successful in preventing recurrent C. diff infection for the next 8 weeks in 95% of participants (95% CI 83.5-99.4%), with 9.8% of the participants reporting ...

Rebyota is a fecal microbiota live-jslm product approved by the FDA for preventing recurrent C. diff infection in the form of a single 150 mL dose administered rectally.Data from more than 1,500 ...